Abstract Library

#4663 CAREFNDR: A phase III, randomised, parallel group, placebo-controlled study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumours

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for carcinoid syndrome (CS) treatment. In a Phase 2, open-label, dose-ranging study, paltusotine reduced the frequency and severity of CS symptoms and was well tolerated (NCT05361668).

Conference:

Presenting Author:

Authors: Kim R, Usiskin K, Fan X, Quock T, Mui C,

Keywords: paltusotine, phase 3 trial, somatostatin receptor agonist, neuroendocrine tumour, carcinoid syndrome,

#4575 Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: Safety and exploratory efficacy results from a phase II, randomised, parallel-group study

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for the treatment of carcinoid syndrome (CS).

Conference:

Presenting Author: Hajac L

Authors: Hajac L, Chauhan A, Mohamed A, Usiskin K, Mui C,

Keywords: paltusotine, phase 2 trial, somatostatin receptor agonist, safety, carcinoid syndrome,

#4060 Interim safety and exploratory efficacy results of a phase 2, randomised, parallel-group study of oral Paltusotine treatment in subjects with carcinoid syndrome

Introduction: Carcinoid Syndrome (CS) is the most common functional NET syndrome. It is characterized by watery diarrhea or cutaneous flushing. Paltusotine is an investigational once-daily, oral, selective SST2 agonist in development for the treatment of acromegaly and CS. Paltusotine has been shown to maintain IGF-1 control at levels similar to injected depot SRLs.

Conference:

Presenting Author:

Authors: Usiskin K, Chauhan A, Mui C, Dillon J, Fan X,

Keywords: oral, paltusotine, carcinoid syndrome, phase II,

#3871 A phase 2, randomized, parallel-group study to evaluate the safety, pharmacokinetics, and dose response of paltusotine treatment in patients with carcinoid syndrome

Introduction: While long-acting somatostatin receptor ligands (SRLs) are mainstay treatments for carcinoid syndrome (CS), symptom relief at labelled doses is inadequate for many patients. Paltusotine is a novel oral, nonpeptide, selective somatostatin receptor type 2 agonist. In patients with acromegaly, paltusotine maintains plasma IGF-1 levels in patients switching from long-acting SRLs. Paltusotine was well tolerated in phase 2 acromegaly studies.

Conference:

Presenting Author:

Authors: Chauhan A, Shaheen S, Usiskin K, Odueyungbo A, Mui C,

Keywords: Paltusotine, Phase 2 trial, Somatostatin receptor agonist, Safety, Pharmacokinetics, Carcinoid syndrome,